A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

PHASE3CompletedINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

February 28, 2007

Conditions
Clostridium EnterocolitisPseudomembranous Colitis
Interventions
DRUG

tolevamer potassium-sodium (GT267-004)

Trial Locations (140)

10016

New York

11040

New Hyde Park

12208

Albany

13210

Syracuse

15212

Pittsburgh

15261

Pittsburgh

17602

Lancaster

18102

Allentown

18901

Doylestown

19140

Philadelphia

19141

Philadelphia

19718

Newark

21201

Baltimore

21740

Hagerstown

22601

Winchester

23249

Richmond

23298

Richmond

24541

Danville

27612

Raleigh

27834

Greenville

28801

Asheville

29401

Charleston

29605

Greenville

30309

Atlanta

30905

Fort Gordon

31405

Savannah

32207

Jacksonville

33511

Brandon

33542

Zephyrhills

33607

Tampa

33744

Bay Pines

34613

Brooksville

37076

Hermitage

39564

Ocean Springs

40202

Louisville

42101

Bowling Green

43608

Toledo

44304

Akron

45459

Centerville

46011

Anderson

46202

Indianapolis

47303

Muncie

47904

Lafayette

48201

Detroit

48202

Detroit

49444

Muskegon

50302

Des Moines

50309

Des Moines

50325

Clive

52002

Dubuque

52242

Iowa City

53226

Milwaukee

54449

Marshfield

54710

Eau Claire

55905

Rochester

57701

Rapid City

58122

Fargo

59701

Butte

59802

Missoula

60064

North Chicago

60141

Hines

60153

Maywood

60634

Chicago

62526

Decatur

63110

St Louis

64111

Kansas City

65646

Everton

70115

New Orleans

70121

New Orleans

72756

Rogers

75702

Tyler

77030

Houston

80204

Denver

80210

Denver

80262

Denver

85006

Phoenix

85012

Phoenix

90073

Los Angeles

90089

Los Angeles

90095

Los Angeles

91505

Burbank

92103

San Diego

92663

Newport Beach

95350

Modesto

95817

Sacramento

96813

Honolulu

98431

Tacoma

80218-1191

Denver

40206-1499

Louisville

02114

Boston

02115

Boston

01608-1320

Worcester

01655

Worcester

03756

Lebanon

07927

Cedar Knolls

07753

Neptune City

07103

Newark

08629

Trenton

05403

Burlington

T2N 2T9

Calgary

T5H 3V9

Edmonton

V1V 1Y5

Kelowna

V1Y 1T2 & V1Y3G8

Kelowna

V5Z 3J5

Vancouver

V8R 1J8

Victoria

R3A 1R9

Winnipeg

R3C 0N2

Winnipeg

E1C 6Z8

Moncton

E2K 4L2

Saint John

B3H 2Y9

Halifax

L1S 2J5

Ajax

N1E 4J4

Guelph

L8N 4A6

Hamilton

K7L 3N6

Kingston

N6A 4G5

London

K1H 8L6

Ottawa

K9J 7B3

Peterborough

M1E 4B9

Scarborough Village

P7B 6V1

Thunder Bay

M2K 1E1

Toronto

M3N 2V6

Toronto

M4N 3M5

Toronto

M5G 1X5

Toronto

M5G 2M9 & M5G 1X5

Toronto

N8X 3V6

Windsor

N9A 1E1

Windsor

G7H 5H6

Chicoutimi

J4V 2H1

Green Field Park

G6V 3Z1

Lévis

H1T 2M4

Montreal

H3A 1A1

Montreal

H3G 1A4

Montreal

G1L 3L5

Québec

G1R 2J6

Québec

J6E 2C3

Saint-Charles-Borromée

J2S 4Y8

Saint-Hyacinthe

G1V 4G2

Sainte-Foy

G9A 1Y1

Trois-Rivières

S7K 1J5

Saskatoon

00935

San Juan

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00106509 - A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea | Biotech Hunter | Biotech Hunter